FDA Approves Inavolisib for PIK3CA-Mutated HR+/HER2− MBC
In the approval trial, Genentech's PI3K inhibitor doubled progression-free survival compared with placebo.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-inavolisib-hr-her2%E2%88%92-advanced-breast-2024a1000ilk?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-inavolisib-hr-her2%E2%88%92-advanced-breast-2024a1000ilk?src=rss
Comments
Post a Comment